MacroGenics | MGNX - Assets


MacroGenics reported $270.76M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Genmab DKK 6.46B 122M Jun/2025
Geron USD 570.54M 3.16M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Xencor USD 875.5M 6.68M Dec/2025